Preclinical evaluation of newly identified therapeutic targets in pediatric acute myeloid leukemia

Preclinical study of TARP-directed cellular and nanobody therapy in pediatric AML: improving survival and quality-of-life

Research assignment of Prof. dr. Tim Lammens, framing the ongoing clinical-translational research at the Department of Pediatric Hematology-Oncology and Stem Cell Transplantation

Stichting Me To You : Research Grants Jolien Vanhooren: "Deciphering the role of Nidogen-1 in pediatric acute myeloid leukemia"

The impact of magnetic particulate matter (mPM) pollution as a contributing factor for development of childhood cancer: an in vitro and in vivo molecular and cellular analysis.

A patient derived xenograft (PDX) platform for in vivo evaluation of novel anticancer therapies

Minimal residual disease targeting in T-cell acute lymphoblastic leukemia

Preclinical validation of a less toxic variant for paediatric leukemia

Predisposition in a family with two pediatric patients with Hodgkin lymphoma Non-Burkett

The role of non-coding RNA in juvenile myelomonocytic leukemia

The role of non-coding RNA in juvenile myelomonocytic leukemia

Evaluation of the prognostic value of the leukemic stem cell (LSC) and pre-leukemic hematopoietic stem cell (pre-L HSC) for minimal residual disease monitoring and clinical management of pediatric acute myeloid leukemia patients

Research Assignment dr. Tim Lammens ihkv the ongoing clinical-translational research at the department of Pediatric Hematology-Oncology and Stem Cell Transplantation

The use of a less toxic alternative asparaginase variant to treat metastatic breast cancer